Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
89 hedge funds and large institutions have $223M invested in Antares Pharma, Inc. in 2013 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 33 increasing their positions, 24 reducing their positions, and 21 closing their positions.
72% more call options, than puts
Call options by funds: $947K | Put options by funds: $550K
38% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 24
30% more capital invested
Capital invested by funds: $171M → $223M (+$52M)
8% less funds holding
Funds holding: 97 → 89 (-8)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.6M |
| 2 |
DM
Deerfield Management
New York
|
+$6.06M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$5.01M |
| 4 |
BC
Broadfin Capital
New York
|
+$3.26M |
| 5 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$958K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$467K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$466K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$328K |
| 5 |
Morgan Stanley
New York
|
-$311K |
ATRS Hedge Fund Activity: Q4 2013 in Review
89 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2013, worth a combined $223M — up 30% from $171M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ATRS and 13 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 33 added.
The largest buyer was Millennium Management, adding an estimated $8.6M. The largest seller was THB Asset Management, cutting an estimated $958K.
- 89 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2013, down from 97 in Q3 2013.
- Funds reported $223M of Antares Pharma, Inc. stock for Q4 2013, up 30% quarter-over-quarter.
- 13 funds opened new Antares Pharma, Inc. positions in Q4 2013 and 21 closed out, a net change of -8 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2013 was Millennium Management, an estimated $8.6M added.
- The largest Antares Pharma, Inc. seller in Q4 2013 was THB Asset Management, an estimated $958K sold.
Based on aggregated 13F filings for Q4 2013.